O

nce again, Brent Saunders is standing out from the pharma c-suite crowd.

Over the weekend, the Allergan chief executive was the only head of a major drug maker to publicly say anything about the highly controversial Trump immigration ban. And what Saunders had to say was not supportive, at all, of the move: Allergan, he tweeted, “is strong & bold b/c of diversity. Oppose any policy that puts limitations on our ability to attract the best & diverse talent.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy